ACIU:NSD-AC Immune SA (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.04

Change

+0.05 (+0.83)%

Market Cap

USD 0.44B

Volume

0.21M

Avg Analyst Target

USD 17.00 (+181.46%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-1.23 (-0.37%)

USD135.16B 39.56 31.39
BNTX BioNTech SE

+1.76 (+0.67%)

USD60.07B 13.82 10.18
REGN Regeneron Pharmaceuticals Inc

+8.63 (+1.59%)

USD58.13B 9.81 7.57
VRTX Vertex Pharmaceuticals Incorpo..

+4.61 (+2.55%)

USD47.16B 23.84 15.87
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+15.19 (+4.21%)

USD33.67B N/A N/A
SGEN Seagen Inc

+2.22 (+1.29%)

USD31.29B 53.66 40.74
GMAB Genmab A/S

+0.80 (+1.80%)

USD29.05B 74.96 8.12
ALNY Alnylam Pharmaceuticals Inc

+2.69 (+1.32%)

USD24.23B N/A N/A
RPRX Royalty Pharma plc

+0.68 (+1.84%)

USD23.31B 29.98 12.47

ETFs Containing ACIU

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.83% 75% C 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.83% 75% C 62% D-
Trailing 12 Months  
Capital Gain 29.89% 73% C 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.89% 73% C 54% F
Trailing 5 Years  
Capital Gain -59.63% 33% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.63% 33% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain -4.61% 26% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.61% 26% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 36.54% 78% C+ 50% F
Risk Adjusted Return -12.63% 26% F 14% F
Market Capitalization 0.44B 57% F 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 11.63 43% F 66% D
Price/Book Ratio 2.28 69% D+ 55% F
Price / Cash Flow Ratio -7.31 52% F 69% D+
EV/EBITDA 4.91 40% F 82% B-
Management Effectiveness  
Return on Equity -33.76% 74% C 34% F
Return on Invested Capital -25.08% 74% C 26% F
Return on Assets -19.15% 65% D 20% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.24 94% A 92% A-
Short Percent 5.50% 46% F 31% F
Beta 0.85 73% C 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector